Do analysts recommend MRAI or SERA?

Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 205.56%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger earnings & valuation, MRAI or SERA?

Marpai has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 0.55 -$28.75M -$0.87 N/A Sera Prognostics $57K 1,236.60 -$31.93M -$0.65 N/A

Is MRAI or SERA more profitable?

Marpai has a net margin of -85.70% compared to Sera Prognostics' net margin of -56,385.97%. Marpai's return on equity of 0.00% beat Sera Prognostics' return on equity. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Sera Prognostics -56,385.97% -41.02% -30.95%

Do analysts recommend NAKA or MRAI?

KindlyMD presently has a consensus price target of $30.00, indicating a potential upside of 681.25%. Given KindlyMD's stronger consensus rating and higher possible upside, research analysts plainly believe KindlyMD is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KindlyMD 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, NAKA or MRAI?

Marpai has higher revenue and earnings than KindlyMD. Marpai is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KindlyMD $3.92M 17.05 -$52.23M -$43.20 N/A Marpai $34.87M 0.55 -$28.75M -$0.87 N/A

Is NAKA or MRAI more profitable?

Marpai has a net margin of -85.70% compared to KindlyMD's net margin of -7,397.12%. Marpai's return on equity of 0.00% beat KindlyMD's return on equity. Company Net Margins Return on Equity Return on Assets KindlyMD -7,397.12% -81.32% -54.17% Marpai -85.70% N/A -100.23%

Do analysts rate DCGO or MRAI?

DocGo presently has a consensus price target of $2.38, suggesting a potential upside of 382.72%. Given DocGo's stronger consensus rating and higher possible upside, research analysts plainly believe DocGo is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, DCGO or MRAI?

Marpai has lower revenue, but higher earnings than DocGo. Marpai is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $301.71M 0.16 -$182.40M -$1.91 N/A Marpai $34.87M 0.55 -$28.75M -$0.87 N/A

Is DCGO or MRAI more profitable?

DocGo has a net margin of -62.23% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Marpai -85.70% N/A -100.23%

Do analysts rate MRAI or EUDA?

EUDA Health has a consensus target price of $55.00, suggesting a potential upside of 261.60%. Given EUDA Health's stronger consensus rating and higher possible upside, analysts clearly believe EUDA Health is more favorable than Marpai. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 EUDA Health 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is MRAI or EUDA more profitable?

EUDA Health has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% EUDA Health N/A N/A N/A

Do analysts prefer CCM or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, CCM or MRAI?

Concord Medical Services has higher revenue and earnings than Marpai. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $65.85M 0.31 -$13.27M N/A N/A Marpai $34.87M 0.55 -$28.75M -$0.87 N/A

Is CCM or MRAI more profitable?

Concord Medical Services has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Concord Medical Services N/A N/A N/A Marpai -85.70% N/A -100.23%

Marpai (MRAI) Competitors

$0.72 +0.07 (+10.02%)

As of 06/26/2026 03:52 PM Eastern

Compare

MRAI vs. SERA, NAKA, DCGO, EUDA, and CCM

Should you buy Marpai stock or one of its competitors? MarketBeat compares Marpai with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marpai include Sera Prognostics (SERA), KindlyMD (NAKA), DocGo (DCGO), EUDA Health (EUDA), and Concord Medical Services (CCM). These companies are all part of the "healthcare" industry.

How does Marpai compare to Sera Prognostics?

Marpai (NASDAQ:MRAI) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Sera Prognostics has a consensus price target of $5.50, indicating a potential upside of 205.56%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

49.8% of Marpai shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Marpai has a net margin of -85.70% compared to Sera Prognostics' net margin of -56,385.97%. Marpai's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

In the previous week, Sera Prognostics had 3 more articles in the media than Marpai. MarketBeat recorded 3 mentions for Sera Prognostics and 0 mentions for Marpai. Sera Prognostics' average media sentiment score of 0.63 beat Marpai's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
Sera Prognostics	Positive

Marpai has a beta of 4.94, indicating that its share price is 394% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Marpai has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.55	-$28.75M	-$0.87	N/A
Sera Prognostics	$57K	1,236.60	-$31.93M	-$0.65	N/A

Summary

Sera Prognostics beats Marpai on 10 of the 17 factors compared between the two stocks.

How does Marpai compare to KindlyMD?

KindlyMD (NASDAQ:NAKA) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

KindlyMD has a beta of 15.84, meaning that its share price is 1,484% more volatile than the broader market. Comparatively, Marpai has a beta of 4.94, meaning that its share price is 394% more volatile than the broader market.

49.8% of Marpai shares are owned by institutional investors. 24.5% of KindlyMD shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

KindlyMD presently has a consensus price target of $30.00, indicating a potential upside of 681.25%. Given KindlyMD's stronger consensus rating and higher possible upside, research analysts plainly believe KindlyMD is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Marpai has a net margin of -85.70% compared to KindlyMD's net margin of -7,397.12%. Marpai's return on equity of 0.00% beat KindlyMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KindlyMD	-7,397.12%	-81.32%	-54.17%
Marpai	-85.70%	N/A	-100.23%

In the previous week, KindlyMD had 6 more articles in the media than Marpai. MarketBeat recorded 6 mentions for KindlyMD and 0 mentions for Marpai. KindlyMD's average media sentiment score of 0.31 beat Marpai's score of 0.00 indicating that KindlyMD is being referred to more favorably in the media.

Company	Overall Sentiment
KindlyMD	Neutral
Marpai	Neutral

Marpai has higher revenue and earnings than KindlyMD. Marpai is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KindlyMD	$3.92M	17.05	-$52.23M	-$43.20	N/A
Marpai	$34.87M	0.55	-$28.75M	-$0.87	N/A

Summary

KindlyMD beats Marpai on 9 of the 16 factors compared between the two stocks.

How does Marpai compare to DocGo?

DocGo (NASDAQ:DCGO) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

In the previous week, DocGo had 2 more articles in the media than Marpai. MarketBeat recorded 2 mentions for DocGo and 0 mentions for Marpai. DocGo's average media sentiment score of 0.93 beat Marpai's score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Positive
Marpai	Neutral

DocGo has a net margin of -62.23% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Marpai	-85.70%	N/A	-100.23%

56.4% of DocGo shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 3.8% of DocGo shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

DocGo presently has a consensus price target of $2.38, suggesting a potential upside of 382.72%. Given DocGo's stronger consensus rating and higher possible upside, research analysts plainly believe DocGo is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Marpai has lower revenue, but higher earnings than DocGo. Marpai is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$301.71M	0.16	-$182.40M	-$1.91	N/A
Marpai	$34.87M	0.55	-$28.75M	-$0.87	N/A

DocGo has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Marpai has a beta of 4.94, indicating that its share price is 394% more volatile than the broader market.

Summary

DocGo beats Marpai on 10 of the 16 factors compared between the two stocks.

How does Marpai compare to EUDA Health?

Marpai (NASDAQ:MRAI) and EUDA Health (NASDAQ:EUDA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

49.8% of Marpai shares are held by institutional investors. Comparatively, 4.3% of EUDA Health shares are held by institutional investors. 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

EUDA Health has lower revenue, but higher earnings than Marpai. EUDA Health is trading at a lower price-to-earnings ratio than Marpai, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.55	-$28.75M	-$0.87	N/A
EUDA Health	$6.82M	6.68	-$2.77M	-$2.40	N/A

EUDA Health has a consensus target price of $55.00, suggesting a potential upside of 261.60%. Given EUDA Health's stronger consensus rating and higher possible upside, analysts clearly believe EUDA Health is more favorable than Marpai.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
EUDA Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, EUDA Health had 3 more articles in the media than Marpai. MarketBeat recorded 3 mentions for EUDA Health and 0 mentions for Marpai. EUDA Health's average media sentiment score of 0.96 beat Marpai's score of 0.00 indicating that EUDA Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
EUDA Health	Positive

EUDA Health has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
EUDA Health	N/A	N/A	N/A

Marpai has a beta of 4.94, meaning that its stock price is 394% more volatile than the broader market. Comparatively, EUDA Health has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

Summary

EUDA Health beats Marpai on 9 of the 15 factors compared between the two stocks.

How does Marpai compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Concord Medical Services has higher revenue and earnings than Marpai.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.31	-$13.27M	N/A	N/A
Marpai	$34.87M	0.55	-$28.75M	-$0.87	N/A

Concord Medical Services has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Marpai has a beta of 4.94, indicating that its stock price is 394% more volatile than the broader market.

49.8% of Marpai shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Concord Medical Services had 1 more articles in the media than Marpai. MarketBeat recorded 1 mentions for Concord Medical Services and 0 mentions for Marpai. Concord Medical Services' average media sentiment score of 0.75 beat Marpai's score of 0.00 indicating that Concord Medical Services is being referred to more favorably in the media.

Company	Overall Sentiment
Concord Medical Services	Positive
Marpai	Neutral

Concord Medical Services has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Concord Medical Services beats Marpai on 8 of the 11 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	health & allied services, not elsewhere classified Industry	Business Sector	NASDAQ Exchange
Market Cap	$19.03M	$87.38M	$6.81B	$12.22B
Dividend Yield	N/A	N/A	3.20%	6.13%
P/E Ratio	-0.27	0.78	28.46	24.18
Price / Sales	0.55	0.32	381.36	113.35
Price / Cash	N/A	4.19	22.95	54.37
Price / Book	-0.42	0.16	5.74	6.36
Net Income	-$28.75M	$25.15M	$206.96M	$337.99M
7 Day Performance	8.48%	6.26%	-0.47%	0.10%
1 Month Performance	6.73%	4.00%	-2.20%	-0.11%
1 Year Performance	-47.03%	-37.90%	26.83%	27.61%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$0.72 +10.0%	N/A	-50.7%	$19.03M	$34.87M	N/A	150
SERA Sera Prognostics	3.8881 of 5 stars	$1.80 -2.2%	$5.50 +205.6%	-9.1%	$72.05M	$80K	N/A	120
NAKA KindlyMD	4.1346 of 5 stars	$4.05 +3.6%	$30.00 +640.7%	-99.3%	$68.04M	$1.82M	N/A	N/A
DCGO DocGo	3.4212 of 5 stars	$0.50 -0.4%	$2.38 +370.8%	-70.9%	$50.04M	$322.20M	N/A	3,568	High Trading Volume
EUDA EUDA Health	2.4229 of 5 stars	$14.90 +4.2%	$55.00 +269.1%	-78.8%	$42.82M	$6.82M	N/A	2	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. SERA, NAKA, DCGO, EUDA, and CCM

How does Marpai compare to Sera Prognostics?

Summary

How does Marpai compare to KindlyMD?

Summary

How does Marpai compare to DocGo?

Summary

How does Marpai compare to EUDA Health?

Summary

How does Marpai compare to Concord Medical Services?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. SERA, NAKA, DCGO, EUDA, and CCM

How does Marpai compare to Sera Prognostics?

Do analysts recommend MRAI or SERA?

Do institutionals & insiders believe in MRAI or SERA?

Is MRAI or SERA more profitable?

Does the media prefer MRAI or SERA?

Which has more volatility and risk, MRAI or SERA?

Which has stronger earnings & valuation, MRAI or SERA?

Summary

How does Marpai compare to KindlyMD?

Which has more volatility & risk, NAKA or MRAI?

Do insiders and institutionals have more ownership in NAKA or MRAI?

Do analysts recommend NAKA or MRAI?

Is NAKA or MRAI more profitable?

Does the media refer more to NAKA or MRAI?

Which has stronger valuation and earnings, NAKA or MRAI?

Summary

How does Marpai compare to DocGo?

Does the media refer more to DCGO or MRAI?

Is DCGO or MRAI more profitable?

Do institutionals and insiders hold more shares of DCGO or MRAI?

Do analysts rate DCGO or MRAI?

Which has better earnings & valuation, DCGO or MRAI?

Which has more volatility & risk, DCGO or MRAI?

Summary

How does Marpai compare to EUDA Health?

Do insiders and institutionals have more ownership in MRAI or EUDA?

Which has stronger earnings & valuation, MRAI or EUDA?

Do analysts rate MRAI or EUDA?

Does the media favor MRAI or EUDA?

Is MRAI or EUDA more profitable?

Which has more volatility and risk, MRAI or EUDA?

Summary

How does Marpai compare to Concord Medical Services?

Which has better earnings and valuation, CCM or MRAI?

Which has more volatility & risk, CCM or MRAI?

Do institutionals & insiders believe in CCM or MRAI?

Does the media favor CCM or MRAI?

Is CCM or MRAI more profitable?

Do analysts prefer CCM or MRAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools